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Overexpression of HER-2 receptor is associated with poor prognosis and aggressive forms of breast cancer. Scientiﬁc literature
indicates a preventive role of isoﬂavones in cancer. Since activation of HER-2 receptor initiates growth-promoting events in cancer
cells, we studied the eﬀect of biochanin A (an isoﬂavone) on associated signaling events like receptor activation, downstream
signaling, and invasive pathways. HER-2-positive SK-BR-3 breast cancer cells, MCF-10A normal breast epithelial cells, and NIH-
3T3 normal ﬁbroblast cells were treated with biochanin A (2–100μM) for 72 hours. Subsequently cell viability assay, western
blotting and zymography were carried out. The data indicate that biochanin A inhibits cell viability, signaling pathways, and
invasive enzyme expression and activity in SK-BR-3 cancer cells. Biochanin A did not inhibit MCF-10A and NIH-3T3 cell viability.
Therefore, biochanin A could be a unique natural anticancer agent which can selectively target cancer cells and inhibit multiple
signaling pathways in HER-2-positive breast cancer cells.
Copyright © 2009 Vikas Sehdev et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Breast cancer is the most frequently diagnosed and second-
most morbid form of cancer aﬄicting women in the USA.
[1]. Breast cancer is a heterogeneous disease with various
subtypes exhibiting diﬀerential susceptibility to anticancer
drugs. Therefore, therapy targeting the speciﬁc breast cancer
s u b t y p ei sr e c o m m e n d e df o re ﬀective treatment [2, 3].
During the normal course of cellular life-cycle cells grow,
diﬀerentiate, and die. These three fundamental stages of
the cellular life-cycle are highly regulated in normal cells
whereas uncontrolled growth, dediﬀerentiated morphology,
andresistancetodeatharethehallmarksofcancercells[4,5].
Breast cancer cells also exhibit deregulated signaling path-
ways that promote uncontrolled growth, impart resistance to
cell death, and induce invasion into the surrounding tissues
[6].
Breast cancer cell proliferation is known to be regulated
by two main families of receptors: (1) hormonal receptors
( e s t r o g e nr e c e p t o ro rE Ra n dp r o g e s t e r o n er e c e p t o ro rP R )
and (2) receptor tyrosine kinases or RTKs (like human
epidermal growth factor receptors or HERs) [7]. Based on
the receptors present, tumors of the breast can be broadly
classiﬁed into (a) luminal A subtype (ER and/or PR-, HER-
2-), (b) luminal B subtype (ER+ and/or PR+, sometimes
HER-2+), (c) HER-2/ER- subtype (HER-2+ and ER-/PR-),
and (c) basal subtype (ER-/PR-/HER-2-) breast cancer
[8]. HER-2/ER- and basal subtypes of breast cancer are
aggressive, resistant to antihormonal therapy and have poor
prognosis as compared to luminal A and luminal B subtypes
of breast cancer [8, 9]. The hormone receptor negative
breast cancer subtypes (HER-2/ER- and basal) respond to
chemotherapeuticdrugs;however,HER-2/ER-isindicatedto
be relatively resistant to chemotherapeutic drugs [10].
TheaboveobservationsindicatethatHER-2overexpress-
ing breast tumors are diﬃcult to treat. HER-2 (also known
as EGFR2/erbB-2) receptor is a proto-oncogene which
belongs to the HER-family of RTKs [11]. The HER-family
of RTKs initiates transient potent downstream signaling
events which regulate growth, viability, and morphogenesis2 Journal of Oncology
of normal breast epithelial cells [12]. Overexpression and/or
ampliﬁcation of HER-2 proto-oncogene is observed in about
30% of all the breast cancer cases [13]. Since HER-2
receptor is the most favored dimerizing partner for other
HER-family of receptors, elevated levels of HER-2 receptor
activity can mediate cellular proliferation [11]. Therefore,
HER-2 receptor and its downstream signaling pathways are
important therapeutic targets for breast cancer therapy.
Various genetic and epigenetic factors inﬂuence breast
cancer incidence by modulating expression and/or activity
of proto-oncogenes and tumor suppressor genes [14, 15].
Genetic factors account for about 5%–10% of breast cancer
cases whereas epigenetic factors like diet play a major
role in breast cancer incidence [16, 17]. Population-based
epidemiological studies on an international scale indicate
that breast cancer incidence and mortality rates in Asian
populations are lower than that in the US population [18].
When Asians migrate to USA, their incidence for breast
cancer increases over a period of several generations and
becomes similar to that of the American population [17,
19]. Epigenetic factors like change in food habits have
been implicated for increase in breast cancer incidence
[17]. Doll and Peto [20]a n dW i l l e t t[ 21, 22]h a v er e p o r t e d
that about 32% of cancer cases could be avoided by dietary
modiﬁcations [20–22].
Consumption of diets rich in fruits, green leafy vegeta-
bles, and soy-based products has been correlated with low
breast cancer incidence in certain subsets of populations
[23–25]. Rich in isoﬂavones, soy, soy-based products, chick
peas, and lentils constitutes a major source of protein in
Asian diets. Elevated serum levels of isoﬂavones due to
consumption of isoﬂavone-rich dietary ingredients has been
correlatedwithareducedriskofbreastcanceramongwomen
in China, Japan and The Netherland [26–28].
Isoﬂavones are generally well tolerated and have not
exhibited toxicity in humans [29]. Genistein is one of the
most widely studied isoﬂavones. Genistein is indicated to
inhibit growth of ER+ and HER-2+ breast cancer cells,
delay onset of spontaneous mammary tumors in MMTV-
neumousemodel,inducecellulardiﬀerentiation,andinhibit
cell cycle progression in ER+ and HER-2+ breast cancer
cells [30–35]. However, genistein has shown mutagenic
activity in mouse lymphoma assay and Chinese hamster
V79 cells [36, 37]. Genistein-mediated irreversible inhibition
of Topoisomerase-II activity could result in the indicated
mutagenic eﬀect [36]. Biochanin A, an isoﬂavone found in
red clover, has been shown to prevent genistein’s mutagenic
eﬀect in Chinese hamster V79 cells [38]. Additionally, in
vitro experiments with HMECs (primary human mammary
epithelia cells), MCF-12A (a nontumorigenic immortalized
breast epithelial cell line), and MCF7 (ER-positive breast
cancer cell line) cells indicate that biochanin A primarily
induces expression of favorable tumor suppressor genes
in HMEC and MCF 12A cell lines [39]. Since biochanin
A is better tolerated and has favorable protein expression
eﬀects as compared to genistein, we studied the eﬀect of
biochanin A on pathways critical for cancer cell growth,
viability, and metastasis. Our previous data indicate that
biochanin A can inhibit growth and survival regulating
pathways in oral squamous cell carcinoma cells [40]. The
goal of this study was to determine the eﬀect of biochanin A
treatment on pathways regulating cellular viability, invasion,
and growth in HER-2-positive (HER-2+) breast cancer
cells. Our hypothesis is that “biochanin A inhibits HER-
2 receptor activation, cytoplasmic signaling pathways, and
transcriptional factors associated with growth, viability, and
invasion of HER-2+ SK-BR-3 breast cancer cells”.
2.MaterialsandMethods
2.1. Cell Culture and Cell Lines. SK-BR-3, MCF-10A, and
NIH-3T3 cell lines were obtained from American Type
Culture Collection (ATCC). SK-BR-3 breast cancer cell line
was maintained as a monolayer culture in RPMI-1640 cell
culture medium supplemented with 10% (v/v) fetal bovine
serum (FBS). The SK-BR-3 breast cancer cell line is ER-, PR-,
and overexpresses HER-2 receptor protein [41]. The MCF-
10A-immortalized breast epithelial cell line was cultured
in DMEM/F12 (1 : 1) cell culture media supplemented
with 5% (v/v) horse serum, insulin (10μg/mL), epider-
m a lg r o w t hf a c t o r( 2 0n g / m L ) ,h y d r o c o r t i s o n e( 0 . 5μg/mL),
cholera toxin (100ng/mL) and penicillin-streptomycin
(100μg/mL each) according to the protocol suggested
by Zientek-Targosz et al. [42] and Debnath et al. [43]. MCF-
10A breast epithelial cells are devoid of HER-2 receptor
protein [44]. The NIH-3T3 normal ﬁbroblast cell line was
cultured in DMEM cell culture media supplement with 10%
(v/v) FBS.
2.2.PharmacologicalTreatments. BiochaninA(D2016)stock
solutions were prepared with dimethy sulfoxide or DMSO
(D4540) as the vehicle. Individual stock solutions were
prepared for each biochanin A ﬁnal treatment concentration
of 2, 5, 10, 20, 50, 60, 70, 80, 90, and 100μM so that the ﬁnal
volume of DMSO was same in all the treatments. Cells were
treated once with biochanin A for 72 hours.
2.3. Antibodies. The following antibodies were procured
from Santa Cruz Biotechnology (Santa Cruz, CA) and Cell
Signaling Technology Inc. (Danvers, MA): Akt (SC-8312),
p-Akt (SC-16646-R), β-Actin (SC-47778), Erk (SC-094), p-
Erk (SC-7976-R), HER-2 (SC-284), p-HER-2 (SC-12352-R),
mTOR (SC-8319), p-mTOR (2971), NFκB (SC-109), and
MT-MMP-1 (SC-12367).
2.4. MTT Cell Viability Assay. SK-BR-3/NIH-3T3 and MCF-
10A cells were seeded at 2000 and 5000cells/well, respec-
tively, into 96-well plates. The plated cells were treated with
biochanin A (2–100μM) and incubated for 72 hours at 37◦C
and 5% CO2 level in an incubator (NuAire Inc., Plymouth,
MN). Subsequently, 20μLo fM T Tr e a g e n t( 5 m g / m Li n
phosphate buﬀered saline pH 7.2 or PBS) was added into
each well and the plates were incubated for 4 hours. The
violet colored formazan crystals formed in each well were
dissolved in 50μL of dimethyl sulfoxide (DMSO). The
absorbance of dissolved formazan crystals was measured
at 540nm in a plate-reader (Bio-Tek PowerWave, BioTekJournal of Oncology 3
Instruments, Inc., Winooski, VT). The intensity of the signal
is a measure of overall cellular metabolic activity and an
indicator of viable cells present at the end of the treatment.
2.5. Western Blot Analysis. SK-BR-3 breast cancer cells were
treated with biochanin A (2–50μM) for 72 hours and cell
lysates prepared using cell lysis buﬀer (containing 1% (v/v)
Triton X-100, 10mM Tris base pH 7.6, 5mM EDTA, 50mM
sodium chloride, 30mM sodium pyrophosphate, 50mM
sodium ﬂuoride, 0.1% (w/v) sodium azide, 50mM phenyl
methyl sulfonyl ﬂuoride, 0.5mg/mL aprotinin, 2.5mg/mL
leupeptin, and 100mM sodium orthovandate in distilled
water at pH 7.6). Protein concentration was determined
using BioRad reagents (Bradford dye) with photometric
analysis at 570nm. Twenty ﬁve microgram of cell lysate
proteins and 10μL of protein ladder (Boston Bioproducts,
Worcester, MA) were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred on to polyvinylidene ﬂuoride membrane (PVDF)
(Millipore, Bedford, MA). The membranes were incubated
with a primary antibody against total and phosphorylated
proteins (HER-2, mTOR, Erk, Akt, NFκBo rM T - M M P 1 )
(Santa Cruz Biotechnology, Santa Cruz, CA and Cell Signal-
ing, Boston, MA) at 1 : 500 dilution in 5% (w/v) bovine
serum albumin (BSA) and 0.01% (w/v) sodium azide in
double distilled water. The membrane was then treated with
horseradish peroxidase-linked secondary antibody at 1 :
5000 dilution in 5% milk solution in Tris buﬀered saline
containing 0.1% (v/v) Tween-20 (TBST) for 45 minutes
at room temperature. The blots were then developed by
using chemiluminescence reagents (Pierce Biotechnology,
Rockford, IL), according to the manufacturer’s protocol and
autoradiographed. The blots were scanned to determine the
relative intensities of the protein bands using UNSCAN-IT
software version 6.1 (Silk Scientiﬁc, Orem, UT). Western
blot analysis using an antibody against β-Actin (Santa Cruz
Biotechnology, Santa Cruz, CA) was carried out and its
relative intensity was determined by UNSCAN-IT. The β-
Actin band data were used to normalize the band inten-
sities of protein loaded into each lane of the separation
gel.
2.6. Gelatin Zymography. 3×106 SK-BR-3 breast cancer cells
were seeded in a T-75 tissue culture ﬂask in RPMI-1640
(10% (v/v) FBS) for 24 hours. The cells were then treated
with biochanin A (20 and 50μM) for 72 hours in serum free
RPMI-1640. The serum free conditioned medium was col-
lectedafter72hoursoftreatmentandcentrifuged(1000rpm,
4◦C, 10 minutes) to remove any ﬂoating cellular debris.
The remaining supernatant (25mL) media was freeze dried
overnight and reconstituted with 2.5mL of double distilled
water. The samples were electrophoresed on commercially
available10%(w/v)SDSpolyacrylamidegelsembeddedwith
gelatin (BioRad, Hercules, CA). After electrophoresis, the
gels were washed with renaturation buﬀer (2.5% (v/v) Triton
X-100 solution for 1 hour to remove SDS. Gels were then
incubated over night at 37◦C in the development buﬀer
(50mM Tris-base, 200mM NaCl, 5mM CaCl2, and 0.02%
(w/v) Brij-35 at pH 7.6). The gels were stained with the
staining solution (40% (v/v) methanol, 10% (v/v) acetic
acid, and 0.5% (w/v) coomassie blue and water) for 1 hour
and then destained using a destaining solution (40% (v/v)
methanol, 10% (v/v) acetic acid, and 50% (v/v) water).
Gelatinolytic activity was identiﬁed as transparent (digested)
bands on a blue background. The 72kDa band corresponds
to MMP-2 and the 92kDa band corresponds to MMP-9.
2.7. Statistical Analysis. Data were expressed as arithmetic
means ± standard error of mean. The number of “n”i n
the ﬁgure legends represents the number of independent
experiments. One-way analysis of variance (ANOVA) with
Tu-Key post hoc analysis was used to show statistical dif-
ference between control groups and biochanin A treatment.
All statistical analyses were carried out using Kaleidagraph
4.0 (Synergy software, PA), and P<. 05 was considered as
statistically signiﬁcant.
3. Results
Elevated HER-2 receptor expression and/or activity is
observed in about 30% of breast cancer cases [13]. Clinically,
HER-2+ breast tumor status has been associated with
absence of ER/PR and poor overall therapeutic outcome
[45]. Since the SK-BR-3 breast cancer cells overexpress HER-
2 receptor protein and lack ER and PR, we used SK-BR-
3 breast cancer cell line to study the eﬀect of biochanin A
on HER-2/ER- subtype of breast cancer [41]. The MCF-
10A-immortalized breast epithelial cell line was used as a
normal control breast epithelial cell line because it exhibits
phenotypicalcharacteristicssimilartothoseofnormalbreast
epithelial cells. The MCF-10A cells are nontumorigenic,
requirehormonesandgrowthfactorsforgrowth,formthree-
dimensionalstructuresincollagen,exhibitanchoragedepen-
dent growth, and respond to growth regulatory mechanisms
[43, 46, 47]. In this study we determined the eﬀect of
biochaninAoncellviability,signaling,andinvasivepathways
in SK-BR-3 breast cancer cells. We also studied inhibition
of MCF-10A and NIH-3T3 cell viability with biochanin A
treatment.
3.1. Eﬀect of Biochanin A on SK-BR-3, MCF-10A, and NIH-
3T3 Cell Viability. The cell viability assay data (Figure 1)
indicate that treatment of SK-BR-3 breast cancer cells
with biochanin A (2–100μM) has a biphasic eﬀect on
cancer cell viability. Treatment with 5–20μM biochanin
A induces increased SK-BR-3 breast cancer cell viability
whereas treatment with 50–100μM biochanin A induces
a dose-dependent inhibition of cell viability. In contrast
with SK-BR-3 breast cancer cell line, treatment of MCF-
10A and NIH-3T3 cell lines with biochanin A (2–100μM)
did not inhibit MCF-10A and NIH-3T3 cell viability
(Figure 1).
Current synthesis of literature suggests that HER-family
of receptors initiate intracellular signaling events that play
an important role in the development, proliferation, and
spread of HER-2/ER- subtype of breast cancer. According4 Journal of Oncology
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Figure 1: Eﬀect of biochanin A on MCF-10A, NIH-3T3, and SK-
BR-3 cell viability. SK-BR-3/NIH-3T3 and MCF-10A cells were
seeded at 2000 and 5000 cells/well in a 96-well plate. After 8 hours
of cell adhesion period, the cells were treated with biochanin A
(2–100μM) for 72 hours. The data indicate a biphasic eﬀect of
biochanin A on SK-BR-3 breast cancer cell viability. Biochanin A
did not inhibit MCF-10A and NIH-3T3 cell viability. C: control or
no treatment; DMSO: vehicle (Statistical analysis: One-way Anova,
n = 3, ∗P<. 05).
to our cell viability assay data (Figure 1), biochanin A
mediated biphasic eﬀect on SK-BR-3 breast cancer cell
viability lies within 2–50μM concentration range. Therefore,
we determined the eﬀect of biochanin A on SK-BR-3 breast
cancer cell signaling by treating the cells with 2–50μM
biochanin A.
3.2. Biochanin A Inhibits HER-2 Receptor Activation. A
comprehensive review by Ross et al. in 2003 of 80 published
clinical studies suggested a strong correlation between HER-
2 overexpression and poor breast cancer patient viability
rates [45]. Increased level of HER-2 receptor protein has also
been associated with aggressive and malignant form of breast
cancer with high morbidity rates [45]. Western blot analysis
was carried out to determine changes in levels of total
or phosphorylated HER-2 protein. Western blotting data
(Figure 2) with HER-2 speciﬁc antibody indicate inhibition
of HER-2 receptor phosphorylation with 50μM( 7 .93±5.27;
P<. 05) biochanin A treatment.
Reduced HER-2 receptor activation with biochanin A
could further result in inhibition of downstream signaling
pathways regulating growth, viability, and invasion.
3.3. Biochanin A Inhibits Erk1/2 (MAPK) Activation. The
Erk1/2 (extracellular signal regulated kinase) pathway is one
of the major downstream signaling pathways associated with
potentmitogeniceﬀect[48].Westernblottingdata(Figure 3)
with Erk1/2 speciﬁc antibody indicate suppression of Erk1/2
phosphorylation with 50μM( 3 1 .27 ± 16.71; P<. 05)
biochanin A treatment in SK-BR-3 breast cancer cells.
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Figure 2: Eﬀect of biochanin A on HER-2 and p-HER-2 protein
expression. (a) SK-BR-3 breast cancer cells were seeded in a T-75
ﬂask in RPMI-1640 cell culture media (10% FBS). Following 72
hoursoftreatmentwithbiochaninA(2–50μM)HER-2andp-HER-
2proteinexpressionwasevaluated.ThedataindicatereducedHER-
2 phosphorylation with 50μM biochanin A (7.93 ± 5.27; P<. 05).
C: control or no treatment; DMSO: vehicle (Statistical analysis: One-
way Anova, n = 3, ∗P<. 05). (b) Representative blot for HER-2 and
p-HER-2 protein expression.
3.4. Biochanin A Inhibits Akt and mTOR Activation. The Akt
pathway is another major downstream signaling pathway
associated with cellular growth and viability [49]. Western
blotting data (Figure 4) with Akt speciﬁc antibody indicate
inhibition of Akt phosphorylation with 50μM( 1 0 .17±7.89;
P<. 05) biochanin A treatment in SK-BR-3 breast cancer
cells.
Phosphorylated Akt can subsequently activate the down-
stream mTOR signaling pathway which regulates cell cycle
progession [49, 50]. The mTOR protein expression data
(Figure 5) with phospho-speciﬁc mTOR antibody indicate
inhibition of mTOR phosphorylation with 50μM biochanin
Atreatment(42.26±12.18;P<. 05)inSK-BR-3breastcancer
cells.
Erk1/2, Akt, and mTOR signaling pathways can subse-
quently modulate eﬀector transcriptional factor expression
and/or activity.Journal of Oncology 5
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Figure 3: Eﬀect of biochanin A on Erk1/2 and p-Erk1/2 protein
expression. (a) SK-BR-3 breast cancer cells were seeded in a T-
75 ﬂask in RPMI-1640 cell culture media (10% FBS). Following
72 hours of treatment with biochanin A (2–50μM) Erk1/2 and p-
Erk1/2 protein expression was evaluated. The data indicate reduced
Erk1/2 phosphorylation at 50μM biochanin A (31.27 ± 16.71; P<
.05). C: control or no treatment; DMSO: vehicle (Statistical analysis:
One-way Anova, n = 3, ∗P<. 05). (b) Representative blot for
Erk1/2 and p-Erk1/2 protein expression.
3.5. Biochanin A Inhibits NFκB Transcriptional Factor Expres-
sion. NFκB is a transcriptional factor found to be constitu-
tively active in HER-2-positive breast cancer subtype [51].
Westernblottingdata(Figure 6)withNFκBspeciﬁcantibody
indicate suppression of NFκB expression after treating SK-
BR-3 cells with 20 (49.93±5.41; P<. 05) and 50μM( 4 4 .53±
6.44; P<. 05) biochanin A (Figure 6).
Elevated oncogenic signaling has been associated with
malignant transformation of breast cancer cells. Malignant
cancer cells are indicated to overexpress matrix metallo-
proteases (MMPs) which aid in the process of tumor cell
invasion and migration.
3.6. Biochanin A Inhibits MMP-9 Activity and MT-MMP1
Expression. MMPs facilitate cancer cell movement into the
surrounding region by digesting the extracellular matrix
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Figure 4: Eﬀect of biochanin A on Akt and p-Akt protein
expression. (a) SK-BR-3 breast cancer cells were seeded in a T-75
ﬂask in RPMI-1640 cell culture media (10% FBS). Following 72
hours of treatment with biochanin A (2–50μM) Akt and p-Akt
protein expression was evaluated. The data indicate reduced Akt
phosphorylation at 50μM( 1 0 .17 ± 7.89; P<. 05) biochanin A. C:
controlornotreatment;DMSO:vehicle(Statisticalanalysis:One-way
Anova, n = 3, ∗P<. 05). (b) Representative blot for Akt and p-Akt
protein expression.
(ECM) components around the tumor cells (Ref). The
MMP gelatinase activity or gelatin zymography assay data
(Figure 7) indicate inhibition of MMP-9 enzyme activity in
SK-BR-3 cells treated with 50μM biochanin A (2.28 ± 2.28;
P<. 05).
MT-MMP1 or MMP-14 is required for activation of
matrix metalloproteases (MMPs) [52]. Western blotting
data (Figure 8) with MT-MMP1 speciﬁc antibody indicate
inhibitionofMT-MMP1enzymeexpressioninSK-BR-3cells
treatedwith10(19.22±9.93;P<. 05)and50μM(2.39±2.30;
P<. 05) biochanin A (Biochanin A: 10μM → 19.22 ± 9.93;
50μM → 2.39 ± 2.30; P<. 05) (Figure 8). Biochanin A-
mediated inhibition of MMP-9 enzyme activity and MT-
MMP1 protein expression suggests that biochanin A can
block invasion promoting signaling mechanisms in SK-BR-
3 breast cancer cells.6 Journal of Oncology
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Figure 5: Eﬀect of biochanin A on mTOR and p-mTOR protein
expression. (a) SK-BR-3 breast cancer cells were seeded in a T-75
ﬂask in RPMI-1640 cell culture media (10% FBS). Following 72
hours of treatment with biochanin A (2–50μM) mTOR and p-
mTOR protein expression was evaluated. The data indicate reduced
mTOR phosphorylation at 50μM biochanin A (42.26 ± 12.18; P<
.05). C: control or no treatment; DMSO: vehicle (Statistical analysis:
One-way Anova, n = 3, ∗P<. 05). (b) Representative blot for
mTOR and p-mTOR protein expression.
4. Discussion
Uncontrolled growth, resistance to chemotherapeutic drugs,
and tumor invasion are the major limiting factors preventing
successful chemotherapeutic outcome. Elevated activity of
HER-2 receptor plays a major role in promoting growth,
viability, and invasion regulating signaling mechanisms in
HER-2/ER- subtype of breast cancer [53]. HER-2 is the
favoreddimerizingpartnerfortheHER-familymembersand
an important therapeutic target for breast cancer treatment.
Increase in HER-2 receptor expression has been shown to
enhance bladder cancer cell sensitivity to physiological levels
of isoﬂavones [54]; therefore, suggesting HER-2 receptor
as a biochemical target for isoﬂavones [54]. Genistein,
the most widely studied isoﬂavone, is indicated to inhibit
receptor tyrosine kinase activity, HER-2 receptor activation,
downstream signaling pathways, and delay onset of spon-
taneous mammary tumors in MMTV/neu mouse model
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Figure 6: Eﬀect of biochanin A on NFκB protein expression.
(a) SK-BR-3 breast cancer cells were seeded in a T-75 ﬂask in
RPMI-1640 cell culture media (10% FBS). Following 72 hours of
treatment with biochanin A (2–50μM) NFκB protein expression
was evaluated. The data indicate reduced NFκB expression at 20
and 50μM biochanin A (Biochanin A: 20μM → 49.93 ± 5.41;
50μM → 44.53 ±6.44; P<. 05). C: control or no treatment; DMSO:
vehicle (Statistical analysis: One-way Anova, n = 3, ∗P<. 05). (b)
Representative blot for NFκB protein expression.
[32, 34, 55]. Unlike genistein, biochanin A is indicated to
be nonmutagenics and prevent genistein-induced mutagenic
eﬀect [36, 38]. Since biochanin A is a methyl derivative of
genistein, we hypothesized that biochanin A inhibits HER-
2 receptor activation and downstream signaling pathways
associated with growth, viability, and invasion of HER-2+
breast cancer cells. We also studied the relative cytotoxic
eﬀectofbiochaninAtreatmentonSK-BR-3breastcancercell
and MCF-10A normal breast epithelial cell viability.
Totestourhypothesiswecarriedoutcellviabilityanalysis
by treating SK-BR-3 and MCF-10A cells with biochanin A
(2–100μM). The data (Figure 1) suggest that biochanin A
selectively inhibits SK-BR-3 breast cancer cells as compared
to MCF-10A normal breast epithelial and NIH-3T3 normal
ﬁbroblast cells. It also indicates that biochanin A has a
biphasic eﬀect on SK-BR-3 cell viability with increased
cell viability at subapoptotic concentrations (2–20μM) and
a dose dependent inhibition of cell viability at higher
concentrations (50–100μM). The increased cellular viability
observed with subapoptotic concentrations of isoﬂavones
like genistein and resveratrol could be due to increased
mitochondrial number and/or activity, induction of cellular
diﬀerentiation, and/or cell cycle arrest in G2/M phase [56–
59]. Isoﬂavone-induced proliferative eﬀect on ER+ MCF-7Journal of Oncology 7
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Figure 7: Eﬀect of biochanin A on MMP-2 and MMP-9 activity. (a)
SK-BR-3 breast cancer cells were seeded in a T-75 ﬂask in RPMI-
1640 cell culture media (10% FBS) for 24 hours. Subsequently they
were treated for 72 hours with biochanin A (20 and 50μM) in
serum free conditions and MMP-2 and MMP-9 gelatinase enzyme
activity was evaluated. The data indicate reduced MMP-9 activity
with 50μM biochanin A (2.28 ± 2.28; P<. 05). C: control or no
treatment; DMSO: vehicle; PL: protein ladder (Statistical analysis:
One-way Anova, n = 3, ∗P<. 05). (b) Representative gelatin gel
for MMP-2 and MMP-9 activity.
cellsinvitroandrodentmodelsinvivohasbeenattributedto
their weak estrogenic activity at subapoptotic concentrations
[60].
Since HER-2 receptor plays an important role in reg-
ulating growth, viability, and invasion regulating signaling
mechanisms in HER-2/ER- subtype of breast cancer, we
determinedtheeﬀectofbiochaninAonHER-2receptoracti-
vationinSK-BR-3breastcancercells.Ourproteinexpression
data (Figure 2) indicate that 50μM biochanin A treatment
signiﬁcantly inhibits HER-2 receptor activation (7.93 ±5.27;
P<. 05).ActivatedHER-2receptorinitiatesgrowth,viability,
and invasion promoting downstream signaling pathways
[53]. In this study we determined the eﬀect of biochanin A
on two major downstream signaling pathways which could
be activated by HER-2 receptor: (1) the Erk1/2 pathway, and
(2) the Akt/mTOR pathway.
Constitutive over-activity of the Erk1/2 pathway has
been observed in both breast cancer tissue and cell lines
as compared to normal tissues and cells [48, 61, 62].
Moreover, increased activity of the Erk1/2 pathway is
associated with drug resistance, cellular proliferation, and
increased metastasis in breast cancer cells [63]. The Akt
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Figure 8: Eﬀect of biochanin A on MT-MMP1 protein expression.
(a)SK-BR-3breastcancercellswereseededinaT-75ﬂaskinRPMI-
1640cellculturemedia(10%FBS).Following72hoursoftreatment
with biochanin A (2–50μM) MT-MMP1 protein expression was
evaluated. Our data indicate reduced MT-MMP-1 expression at
10 and 50μM biochanin A (Biochanin A: 10μM → 19.22 ± 9.93;
50μM → 2.39 ± 2.30; P<. 05). C: control or no treatment; DMSO:
vehicle (Statistical analysis: One-way Anova, n = 3, ∗P<. 05). (b)
Representative blot for MT-MMP-1 protein expression.
pathway is a downstream signaling pathway associated with
resistance to drug induced apoptosis and deregulation of
endogenous cell death mechanisms [49]. Activated Akt
can initiate signaling pathways which can lead to cellular
proliferation and resistance to cell death. An important
downstream signaling pathway activated by Akt is the mTOR
pathway. Increased phosphorylation of mTOR is associated
with increased protein synthesis, a prerequisite for cellular
proliferation [49]. Our protein expression data (Figures 3,
4,a n d5) suggest that biochanin A at 50μM can inhibit
activationoftheErk1/2(31.27±16.71;P<. 05),Akt(10.17±
7.89; P<. 05), and mTOR (42.26±12.18; P<. 05) pathways.
Activation of cytoplasmic signaling pathways (Erk1/2,
Akt, and mTOR) results in activation of transcriptional
factors which mediate expression of speciﬁc proteins. HER-
2-activated Akt pathway has been shown to regulate NFκB
transcriptional factor expression in breast cancer cells [64].
Elevated level of NFκB can promote cellular growth, viability
and malignant transformation [51]. High levels of NFκB
expression have been correlated with HER-2/ER-subtype of
breast cancer. The NFκB protein expression data (Figure 6)
indicate that biochanin A (20 and 50μM) can inhibit NFκB
(Biochanin A: 20μM → 49.93±5.41; 50μM → 44.53±6.44;
P<. 05) expression which is consistent with HER-2/Akt-
mediated regulation of NFκB expression.8 Journal of Oncology
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Figure 9: Pathways inhibited by biochanin A in HER-2+ SK-BR-
3 breast cancer cells. The protein expression data indicate that
biochanin A treatment inhibits growth (p-HER-2, p-Erk), survival
(Akt, mTOR, and NFκB), and invasion (MMP-9 and MMP-14)
promoting pathways in SK-BR-3 cells.
Matrix Metalloproteases (MMPs) are protein-digesting
enzymes with the primary function of breaking down
components (extracellular matrix, ECM) surrounding the
tumor cells. This activity of MMPs is employed by cancer
cells to invade surrounding tissue and metastasize. Elevated
expression of MMP-2 and MMP-9 is positively correlated
with HER-2 overexpression in mammary tumors [65].
The MMP-2 and MMP-9 gelatin zymography assay data
(Figure 7) indicate inhibition of MMP-9 enzyme activity in
SK-BR-3 cells treated with biochanin A.
MT-MMP1 or MMP-14 is required for activation of
matrix metalloproteases (MMPs). MT-MMP1 is a cell mem-
brane localized protease that cleaves the proenzyme or pro-
MMP into its ECM-digesting active enzyme or MMP state.
The activated MMP can then digest its speciﬁc substrate(s)
within the ECM and release growth factors and cytokines for
the growth of invading cancer cells. The MT-MMP1 protein
expression data (Figure 8) indicate that biochanin A can
inhibit MT-MMP1 protein expression in SK-BR-3 cells.
The studies presented in this report indicate that
biochanin A can inhibit multiple signaling pathways associ-
ated with growth, survival, and invasion in HER-2+ breast
cancer cells at supraphysiological concentrations. Previous
in vitro and in vivo (xenograft) studies with MCF-7 breast
cancer cells and biochanin A indicate that, compared to
in vitro concentrations, biochanin A can inhibit in vivo
tumorgrowthatmuchlowerplasmaconcentrations[66,67].
Soy meal diet has also been shown to delay spontaneous
mammary tumor development in MMTV/neu mouse model
[68]. This could be due to preferential accumulation of
biochanin A and/or potent biochanin A metabolites (gen-
erated during in vivo metabolism) in mammary tissue.
Additionally, the cell viability data (Figure 1) indicate that
biochanin A treatment (50–100μM) selectively inhibits SK-
BR-3 breast cancer cell viability without aﬀecting MCF-
10A normal breast epithelial cell and NIH-3T3 normal
ﬁbroblast cell viability. Further characterization of the eﬀect
of biochanin A on cell cycle progression and regulation in
SK-BR-3, MCF-10A, and NIH-3T3 cells will improve our
mechanistic understanding of the selective inhibitory eﬀect
of biochanin A on SK-BR-3 breast cancer cell viability.
5. Conclusion
The HER-2-positive subtype of breast cancer has an aggres-
sive malignant phenotype due to HER-2 signaling cascade
mediated rapid growth, drug resistance, and distant metas-
tasis. This report indicates that biochanin A, a dietary
isoﬂavone, can inhibit HER-2 receptor activation, down-
stream signaling pathways (Erk1/2, Akt, and mTOR), and
NFκB transcription factor expression. Apart from inhibiting
the signaling pathways, biochanin A also inhibits invasive
enzyme activity by suppressing MMP-9 protease activity and
MT-MMP1 protein expression, respectively. The data (as
summarizedinFigure 9)suggestthatbiochaninAisaunique
natural compound which selectively targets HER-2+ SK-BR-
3 breast cancer cells and inhibits multiple deregulated mech-
anismsassociatedwithmalignanttransformation.Therefore,
biochanin A should be studied further to determine if it
canbeusedwithotherconventionalchemotherapeuticdrugs
and/or with HER-2 targeted anticancer drugs for better
therapeutic outcome of patients suﬀering from HER-2/ER-
subtype of breast cancer.
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